The Bridge

Get the latest insights on provider-supplier collaboration

Payers are shifting where patients receive infusions. Here's what that means for 4 key industry players.

Colleen Keenan , Regina Lohr October 23, 2020

Even amid the Covid-19 epidemic, rising drug costs continue to be a major news story. And it's no surprise that this issue is garnering attention—the average annual cost of a specialty chronic drug in 2017 was $79,000. As a result, payers are implementing different strategies to combat these rising drug costs.

Read more »

The supply chain is broken. Keep these 2 insights in mind going forward.

by Erin Lane, Brandi Greenberg, and Nick Hula October 15, 2020

Shortages of personal protective equipment, ventilators, and Covid-19 testing supplies began making headlines in March, but health care supply chain challenges are far from over. Today, the promise of safe and effective Covid-19 vaccines is tempered by serious questions about our ability to produce and distribute the supplies necessary to administer such vaccines at scale.

Read more »

Q&A: What does clinical trial innovation look like in the future?

by Pam Divack and Manasi Kapoor October 14, 2020

This is a second part in a series of Q&A interviews with Optum's Digital Research Network (DRN). Check out our first Q&A with DRN here, or click here to see VirTrial's perspective on clinical trial innovation.

Read more »

Virtual clinical trials are a 'must have' amid Covid-19. Here's why.

by Pam Divack and Manasi Kapoor October 9, 2020

Editor's note: This article is part of a Q&A series about clinical trial innovation during the Covid-19 pandemic. For more related insights, check out our Q&A with Optum's Digital Research Network

Read more »

How life science leaders can support providers' shift to virtual care during Covid-19

by Pam Divack, Colleen Keenan, Erin Lane, and Manasi Kapoor October 6, 2020

As in other industries, Covid-19 has spurred health care to quickly embrace virtual business operations. For care delivery, that means utilizing telehealth, virtual visits, remote monitoring, and other digital tools to treat patients. For life science companies, it means conducting interactions with providers and key customers using virtual channels, rather than relying on traditional in-person interactions. 

Read more »

Q&A: How Covid-19 could reshape clinical trials

by Pam Divack and Manasi Kapoor September 28, 2020

Covid-19 has significantly impacted clinical trials activity around the world.

Read more »

4 ways to segment your IDN customers

by Colleen Keenan and Nicole Winegardner September 16, 2020

The Covid-19 epidemic has upended the way we work, particularly for how suppliers and service providers engage their provider customers—but customer segmentation can help you navigate this new reality.

Read more »

What you need to know about health technology assessments

by Pam Divack, Nick Hula, and Erin Lane June 30, 2020

Our research on value analysis committees (VACs) revealed that roughly half of provider organizations used third-party performance technologies to support the value analysis process in 2019, and over 61% plan on using them in the future. Among these third parties are a growing number of health technology assessment (HTA) organizations.

Read more »